TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05118139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213616
Description: Flavor variant P1213616 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213816
Description: Flavor variant P1213816 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211916
Description: Flavor variant P1211916 of a 1.5% nicotine ENDS product
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05703347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Supportive Feedback
Description: Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05118139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1210016
Description: Flavor variant P1210016 of a 1.5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211217
Description: Flavor variant P1211217 of a 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213417
Description: Flavor variant P1213417 of a 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211222
Description: Flavor variant P1211222 of a 5% nicotine ENDS product
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05118139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213422
Description: Flavor variant P1213422 of a 5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213722
Description: Flavor variant P1213722 of a 5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213622
Description: Flavor variant P1213622 of a 5% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1213822
Description: Flavor variant P1213822 of a 5% nicotine ENDS product
Study: NCT06530654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distraction by dentist
Description: Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction by cartoon movie
Description: Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AG-active distraction group
Description: The active distraction group is treated and interacting with the designed application
Study: NCT06426407

Intervention type: DRUG
Intervention: Vasopressin
Description: Fixed dosage vasopressin ordered as an adjunctive vasopressor to norepinephrine
Study: NCT00540605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: topical gel containing 1% tenofovir
Study: NCT05481034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMA bolus option
Description: SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMA bolus option
Description: SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exactly estimated carbohydrate content bolus option
Description: The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
Study: NCT05118139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1211922
Description: Flavor variant P1211922 of a 5% nicotine ENDS product
Study: NCT05481034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exactly estimated carbohydrate content bolus option
Description: The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
Study: NCT05657639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAV Regimen
Description: Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEC Regimen
Description: Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT04804033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BHV-3500 (zavegepant)
Description: BHV-3500 (zavegepant) softgel capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BHV-3500 (zavegepant)
Description: BHV-3500 (zavegepant) softgel capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo softgel capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo softgel capsule.
Study: NCT06302621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
Study: NCT05431556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual mind-body group exercise classes
Description: Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~* Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~* Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
Study: NCT06430684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
Study: NCT04870554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enteric feeding
Description: All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
Study: NCT05816590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med@HOME Mobile App
Description: Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
Study: NCT05930444

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases
Description: Patients presenting with eye-related chief complaints initially complete a mobile phone application. This application utilizes patient medical history and relevant images (such as selfies and photos from eye examinations) to provide intelligent diagnosis. The diagnosis remains undisclosed to the patients. Subsequently, patients seek medical attention and undergo clinical examination by a skilled clinician. The clinical diagnosis is subsequently reviewed by a second experienced clinician. If the diagnoses align, it is considered the gold standard. In cases of discrepancy, the consensus reached by the two clinicians becomes the gold standard.
Study: NCT05467098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
Study: NCT04195685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB)
Description: Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
Study: NCT05735015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encaleret
Description: Oral administration, twice a day
Study: NCT05118139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P1210022
Description: Flavor variant P1210022 of a 5% nicotine ENDS product
Study: NCT04743635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avéli device
Description: Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avéli device
Description: Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
Study: NCT05566197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet Nusantara
Description: Diet Nusantara consists of 1700 kilocalories (or 500 kilocalories lower than basal energy expenditure) on first month and subsequent reduction for the following months (200 kilocalories). The participants should also limit the sodium intake not more than 2300 mg daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counseling
Description: Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05108324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zygomatic implant
Description: 2 zygomatic implants and 2 anterior conventional implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant
Description: patients will receive 4 conventional dental implant
Study: NCT06332144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural vs. Random sequences of stimuli
Description: Participants will see or listen to sequences of sounds and images either in a structured condition or a random condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intact vs. Degraded speech
Description: Participants will listen to an audiobook Alice in Wonderland in the MRI scanner. The speech is either intact or degraded.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeating 5-syllable nonwords or 2-syllable nonwords
Description: Participants will listen to nonwords (either 5-syllable or 2-syllable) and then repeat them as accurately as possible in the MRI scanner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data.
Description: Participants will read (orthographic serial recall) or listen to (phonological serial recall) strings.
Study: NCT06090435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise plus motor imagery
Description: Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a motor imagery intervention (which consists of imagining the same movements but not performing them for real).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise plus action observation
Description: Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added an action observation intervention (which consists of observing the same movements but not performing them for real).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a sham action observation intervention (which consists of observing planets in space).
Study: NCT06115122

Intervention type: OTHER
Intervention: Pre-eclampsia screening program
Description: Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.

Intervention type: OTHER
Intervention: Pre-eclampsia screening program
Description: Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.

Intervention type: OTHER
Intervention: Pre-eclampsia screening program
Description: Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.

Intervention type: OTHER
Intervention: Pre-eclampsia screening program
Description: Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05481931

Intervention type: DRUG
Intervention: prabotulinumtoxinA
Description: Botulinum toxin Type A powder for solution for injection

Intervention type: DRUG
Intervention: prabotulinumtoxinA
Description: Botulinum toxin Type A powder for solution for injection
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT05481931

Intervention type: DRUG
Intervention: prabotulinumtoxinA
Description: Botulinum toxin Type A powder for solution for injection
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray
Study: NCT05972135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo X-ray
Study: NCT04994431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: 0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
Study: NCT06675227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: electrolyte beverages
Description: Using Electrolyte Beverages as replacement for water to dissolve PEG(2L plan) in bowel preparation process.